Preview

Obesity and metabolism

Advanced search

The assessment of Trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus

https://doi.org/10.14341/omet2017467-72

Abstract

Aim. To estimate the trabecular bone score (TBS) for evaluation of fracture probability in order to make decisions about starting osteoporosis treatment in patients with type 2 diabetes mellitus (T2DM).


Materials and methods. We obtained the bone mineral density (BMD) and trabecular bone score (TBS) using dual energy X-ray absorptiometry (iDXA) in patients with T2DM (with and without a history of osteoporotic fractures) versus the control group. Before and after TBS measurements we assessed the ten-year probability of fracture using the Fracture Risk Assessment Tool (FRAX).


Results. We enrolled 48 patients with T2DM, including 17 with a history of low-traumatic fracture, 31 patients without fractures and 29 subjects of a control group. BMD was higher in patients with T2DM compared to the control group at L1–L4 (mean T-score 0.44, 95% CI -3.2 – 4.9 vs mean T-score 0.33, 95% CI -2.9 – 3.0 in a control group p=0.052) and Total Hip (mean T-score 0.51, 95% CI -2.1 – 3.0 vs mean T-score -0.03, 95% CI -1.4 – 1.2 in a control group p=0,025). The TBS and 10-year probability of fracture (FRAX) was not different in patients with T2DM versus the control group. However, when the TBS was entered as an additional risk factor, the 10-year probability of fracture became higher in patients with T2DM (10-year probability of fracture in T2DM- 8.68, 95% CI 0.3-25.0 versus 6.68, 95% CI 0.4–15.0 in control group, p=0.04). Among patients with diabetes with and without fractures the FRAX score was higher in subjects with fractures, but no difference was found in regards to BMD or TBS. Entering BMD and TBS values into the FRAX tool in subjects with diabetes and fractures decreased the FRAX score. However, patients with low-traumatic fractures should be treated for osteoporosis without a BMD, TBS or FRAX assessment.


Conclusion. TBS improves the results of FRAX assessment in patients with T2DM and should be entered while evaluating FRAX in patients with T2DM. However, additional research is needed to develop a more sensitive tool to evaluate fracture risk in patients with T2DM.

About the Authors

Tatiana O. Yalochkina

City polyclinic №219


Russian Federation

MD, endocrinologist 



Zhanna E. Belaya

Endocrinology Research Centre


Russian Federation

ScD, Head of neuroendocrinology and osteopathy department



Tatiana O. Chernova

Endocrinology Research Centre


Russian Federation

PhD, Researcher at radiology department



Natalia I. Sazonova

Endocrinology Research Centre


Russian Federation

PhD, endocrinologist of radiology department



Natalia V. Tarbaeva

Endocrinology Research Centre


Russian Federation

PhD, radiologist of Diagnostic department



Timur T. Tsoriev

Endocrinology Research Centre


Russian Federation

Postgraduate student



Ludmila Y. Rozhinskaya

Endocrinology Research Centre


Russian Federation

ScD, Professor, Chief Researcher at neuroendocrinology and osteopathy department



Galina A. Mel'nichenko

Endocrinology Research Centre


Russian Federation

ScD, Professor. Head of Clinical Endocrinology Institute


Competing Interests:
 
 


References

1. Koh WP, Wang R, Ang LW, et al. Diabetes and Risk of Hip Fracture in the Singapore Chinese Health Study. Diabetes Care. 2010;33(8):1766-1770. doi: 10.2337/dc10-0067.

2. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and Its Complications and Their Relationship with Risk of Fractures in Type 1 and 2 Diabetes. Calcif Tissue Int. 2008;84(1):45-55. doi: 10.1007/s00223-008-9195-5.

3. Bonds DE, Larson JC, Schwartz AV, et al. Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study. J Clin Endocr Metab. 2006;91(9):3404-3410. doi: 10.1210/jc.2006-0614.

4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2006;18(4):427-444. doi: 10.1007/s00198-006-0253-4.

5. Ялочкина Т.О., Белая Ж.Е., Рожинская Л.Я., и др. Переломы костей при сахарном диабете 2 типа: распространенность и факторы риска. // Сахарный диабет. – 2016. – Т. 19. – № 5. – С. 359-365. [Yalochkina TO, Belaya JEe, Rozhinskaya LY, et al. Bone fractures in patients with type 2 diabetes mellitus: prevalence and risk factors. Diabetes mellitus. 2016;19(5):359-365. (in Russ.)] doi: 10.14341/dm7796.

6. Цориев Т.Т., Белая Ж.Е., Мельниченко Г.А. Трабекулярный костный индекс – неинвазивный метод оценки качества костной ткани на основании рутинной двухэнергетической денситометрии. Перспективы использования в клинической практике. // Альманах Клинической Медицины. – 2016. – Т. 44. – № 4. – С. 462-476. [Tsoriev TT, Belaya ZE, Mel'nichenko GA. Trabecular Bone Score – A non-Invasive Analytical Method to Evaluate Bone Quality Based on Routine Dual-Energy Absorptiometry. Perspectives of Its Use in Clinical Practice. Almanac of Clinical Medicine. 2016;44(4):462-476. (in Russ.)] doi: 10.18786/2072-0505-2016-44-4-462-476.

7. Hans D, Barthe N, Boutroy S, et al. Correlations Between Trabecular Bone Score, Measured Using Anteroposterior Dual-Energy X-Ray Absorptiometry Acquisition, and 3-Dimensional Parameters of Bone Microarchitecture: An Experimental Study on Human Cadaver Vertebrae. J Clin Densitom. 2011;14(3):302-312. doi: 10.1016/j.jocd.2011.05.005.

8. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Краткое изложение клинических рекомендаций по диагностике и лечению остеопороза Российской Ассоциации Эндокринологов. // Остеопороз и Остеопатии. – 2016. – № 3. – С. 28-36. [Melnichenko GA, Belaya ZE, Rozhinskaya LY, et al. Summary of Clinical Guidelines for the Diagnosis and Treatment of Osteoporosis of the Russian Association of Endocrinologists. Osteoporosis and bone diseases. 2016;19(3):28-36. (in Russ.)] doi: 10.14341/osteo2016328-36.

9. Белая Ж.Е., Смирнова О.М., Дедов И.И. Роль физических нагрузок в норме и при сахарном диабете. // Проблемы эндокринологии. – 2005. – Т.51. - №2. – С. 28-37. [Belaya ZhE, Smirnova OM, Dedov II. Rol' fizicheskikh nagruzok v norme i pri sakharnom diabete. Problems of endocrinology. 2005;51(2):28-37. (In Russ.)]

10. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes Is Associated Independently of Body Composition With BMD and Bone Volume in Older White and Black Men and Women: The Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19(7):1084-1091. doi: 10.1359/jbmr.040311.

11. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture. Am J Epidemiol. 2007;166(5):495-505. doi: 10.1093/aje/kwm106.

12. Rabier B, Héraud A, Grand-Lenoir C, et al. A multicentre, retrospective case–control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture. Bone. 2010;46(1):176-181. doi: 10.1016/j.bone.2009.06.032.

13. Winzenrieth R, Dufour R, Pothuaud L, Hans D. A Retrospective Case–Control Study Assessing the Role of Trabecular Bone Score in Postmenopausal Caucasian Women with Osteopenia: Analyzing the Odds of Vertebral Fracture. Calcif Tissue Int. 2009;86(2):104-109. doi: 10.1007/s00223-009-9322-y.

14. Zhukouskaya VV, Ellen-Vainicher C, Gaudio A, et al. The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients. Osteoporos Int. 2015;27(1):49-56. doi: 10.1007/s00198-015-3212-0.

15. Hans D, Šteňová E, Lamy O. The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice. Current Osteoporosis Reports. 2017;15(6):521-531. doi: 10.1007/s11914-017-0410-z.

16. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(S2):407-413. doi: 10.1007/s00198-010-1253-y.

17. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А.. Ибандронат (Бонвива) – новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению – лучший результат. // Остеопороз и остеопатии. – 2006. – № 3. – С. 23-29. [Belaya ZE, Rozhinskaya LY, Melnichenko GA. Ibandronat (Bonviva) – novoe napravlenie v lechenii bisfosfonatami. Luchshaya priverzhennost' k lecheniyu – luchshiy rezul'tat. Osteoporosis and bone diseases. 2006;9(3):23-30. (In Russ.)] doi: 10.14341/osteo2006323-30.


Supplementary files

1. Рис. 1. Определение ТКИ у пациента с СД 2 типа.
Subject
Type Исследовательские инструменты
View (734KB)    
Indexing metadata ▾
2. Рис. 2. Определение дальнейшей тактики ведения пациентов на основании данных FRAX.
Subject
Type Исследовательские инструменты
View (274KB)    
Indexing metadata ▾
3. Рис. 3. Определение дальнейшей тактики ведения пациентов на основании данных FRAX.
Subject
Type Исследовательские инструменты
View (344KB)    
Indexing metadata ▾
4. Рис. 4. Индивидуальная 10-летняя вероятность переломов (FRAX) у пациентов с сахарным диабетом 2 типа при внесении поправки на ТКИ
Subject
Type Исследовательские инструменты
View (76KB)    
Indexing metadata ▾

Review

For citations:


Yalochkina T.O., Belaya Zh.E., Chernova T.O., Sazonova N.I., Tarbaeva N.V., Tsoriev T.T., Rozhinskaya L.Y., Mel'nichenko G.A. The assessment of Trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus. Obesity and metabolism. 2017;14(4):67-72. (In Russ.) https://doi.org/10.14341/omet2017467-72

Views: 1279


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)